←
Erica Barnell248 posts
Erica Barnell avatar

Erica Barnell

@EricaBarnell

MD/PhD | Geneoscopy CMO/CSO | Forbes 30 Under 30

◷ Joined February 2018▧ 25 Photos and videos
Geneoscopy avatar
⟳ Erica Barnell retweeted
Geneoscopy@GeneoscopyCo·29 Apr 2025

FOR IMMEDIATE RELEASE: Geneoscopy Sibling Co-founders Named Finalists for EY Entrepreneur Of The Year 2025 Heartland Award "@EricaBarnell and I have always focused on building a strong business foundation—scaling our operations, hiring the right people to advance our mission and technology, establishing key partnerships, and setting the stage for long-term growth. We're honored to be recognized by EY among such an inspiring group of entrepreneurs." — @AndrewBarnell, MBA, CEO and co-founder of Geneoscopy. Read the full release here: bit.ly/4jslhyN #eoyus #eoyhl @EY_US

Post attachment
Parakkal Deepak MD, MS, FACG avatar
⟳ Erica Barnell retweeted
Parakkal Deepak MD, MS, FACG@P_DeepakIBDMD·19 May 2024

🤩 Day 1 @DDWMeeting for our team across topics: - Single cell analyses/spatial transcriptomics in perianal Crohn’s & Crohn’s IPAA - Eukaryotic stool RNA in predicting disease activity/response - PET CT serial data in perianal fistulas - Clin predictors urgency in UC @SPARCIBD

Post attachmentPost attachmentPost attachmentPost attachment
Dave Messina avatar
⟳ Erica Barnell retweeted
Dave Messina@DaveMessina·7 May 2024

Incredible work by @EricaBarnell, Andrew Barnell, and the whole @GeneoscopyCo team. I've had the opportunity to watch their journey since nearly the start. They are truly outstanding founders who have built an incredible company that will make a huge impact on patients for years to come.

Geneoscopy is thrilled to announce the FDA approval of #colosense, our noninvasive multi-target stool RNA-based #colorectalcancer screening test--the first to use patented #rna technology to provide a dynamic view of disease activity. bit.ly/ColoSenseFDAApproval #earlydetection

Post attachment
JAMA avatar
⟳ Erica Barnell retweeted
JAMA@JAMA_current·24 Oct 2023

In individuals 45 years and older, a multitarget stool RNA test showed high sensitivity for colorectal neoplasia (colorectal cancer and advanced adenoma) with significant improvement in sensitivity relative to the fecal immunochemical test. ja.ma/473Ry8H #acg2023

Post attachment
JAMA avatar
⟳ Erica Barnell retweeted
JAMA@JAMA_current·23 Oct 2023

In individuals 45 years and older, a multitarget stool RNA test showed high sensitivity for colorectal neoplasia (colorectal cancer and advanced adenoma) with significant improvement in sensitivity relative to the fecal immunochemical test. ja.ma/471pOBH #acg2023

Post attachment
Erica Barnell avatar
Erica Barnell@EricaBarnell·23 Oct 2023

I am officially published in @JAMA_current See results from @GeneoscopyCo's CRC-PREVENT clinical trial for our lead assay in colorectal cancer screening (pending FDA approval): jamanetwork.com/journals/jam…